Prognostic and Theranostic Biomarkers in Ovarian Clear Cell Carcinoma.
Wiedemeyer K, Wang L, Kang EY, Liu S, Ou Y, Kelemen LE, Feil L, Anglesio MS, Glaze S, Ghatage P, Nelson GS, Köbel M.
Int J Gynecol Pathol. 2022 Mar 1;41(2):168-179. doi: 10.1097/PGP.0000000000000780.
CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype.
Li H, Luo F, Jiang X, Zhang W, Xiang T, Pan Q, Cai L, Zhao J, Weng D, Li Y, Dai Y, Sun F, Yang C, Huang Y, Yang J, Tang Y, Han Y, He M, Zhang Y, Song L, Xia JC.
J Immunother Cancer. 2022 Mar;10(3):e004029. doi: 10.1136/jitc-2021-004029.
Novel LAMC2 fusion protein has tumor-promoting properties in ovarian carcinoma.
Daisuke H, Kato H, Fukumura K, Mayeda A, Miyagi Y, Seiki M, Koshikawa N.
Cancer Sci. 2021 Dec;112(12):4957-4967. doi: 10.1111/cas.15149. Epub 2021 Nov 5.
'STIC-like' lesions in ovarian low-grade serous carcinoma: a diagnostic pitfall.
Machuca-Aguado J, McCluggage WG.
Histopathology. 2023 Sep;83(3):489-492. doi: 10.1111/his.14967. Epub 2023 Jun 25.
Early and consistent overexpression of ADRM1 in ovarian high-grade serous carcinoma.
Jiang RT, Yemelyanova A, Xing D, Anchoori RK, Hamazaki J, Murata S, Seidman JD, Wang TL, Roden RBS.
J Ovarian Res. 2017 Aug 7;10(1):53. doi: 10.1186/s13048-017-0347-y.
Prognostic value of ALK overexpression and molecular abnormalities in high-grade serous ovarian carcinoma.
Gorczyński A, Miszewski K, Gager Y, Koch S, Pötschke J, Ugrinovski D, Gabert J, Pospieszyńska A, Wydra D, Duchnowska R, Szymanowski B, Cierniak S, Kruecken I, Neumann K, Mirkov K, Biernat W, Czapiewski P.
Cancer Biomark. 2023;38(1):17-26. doi: 10.3233/CBM-230117.
Human Epidermal Growth Factor Receptor 2 Overexpression/Amplification in Primary Ovarian Endometrioid Carcinoma.
Bui CM, Oren A, Balzer B, Maluf H, Medeiros F.
Appl Immunohistochem Mol Morphol. 2024 May-Jun 01;32(5):222-228. doi: 10.1097/PAI.0000000000001194. Epub 2024 Apr 18.
Management of Preinvasive Lesions.
Patrono MG, Corzo C, Iniesta M, Ramirez PT.
Clin Obstet Gynecol. 2017 Dec;60(4):771-779. doi: 10.1097/GRF.0000000000000316.
The role of the fallopian tube in the origin of ovarian cancer.
Erickson BK, Conner MG, Landen CN Jr.
Am J Obstet Gynecol. 2013 Nov;209(5):409-14. doi: 10.1016/j.ajog.2013.04.019. Epub 2013 Apr 10.
HER2 status as a potential predictive biomarker for ovarian clear cell carcinoma.
Kendall Bártů M, Němejcová K, Michálková R, Stružinská I, Hájková N, Hojný J, Krkavcová E, Laco J, Matěj R, Drozenová J, Méhes G, Fabian P, Hausnerová J, Švajdler M, Škapa P, Cibula D, Zima T, Dundr P.
Virchows Arch. 2023 Oct;483(4):497-507. doi: 10.1007/s00428-023-03640-4. Epub 2023 Sep 7.
